Prucalopride 2 mg is a prescription medication approved for treating chronic constipation in adults who do not respond adequately to standard laxatives. It works by stimulating serotonin receptors in the colon to increase intestinal contractions and improve stool passage.
Chronic constipation affects approximately 14% of adults in the United States, according to the American College of Gastroenterology. Prucalopride is specifically indicated for patients with symptomatic constipation lasting at least six months, despite lifestyle changes and over-the-counter laxatives. It is not intended for occasional or mild constipation.
The drug is taken once daily, usually in the morning. It is available only by prescription and requires a healthcare provider's evaluation to confirm diagnosis and rule out structural causes such as bowel obstruction or hypothyroidism. It is not recommended for children under 18 or individuals with severe liver impairment.
Prucalopride is a selective serotonin 5-HT4 receptor agonist. These receptors are located in the enteric nervous system of the large intestine. When activated, they improve peristalsis-the wave-like muscle contractions that move stool through the colon.
Unlike stimulant laxatives such as senna, which act on the colonic epithelium and may cause cramping, prucalopride targets neural pathways responsible for coordinated bowel movements. This results in more physiologic stool transit without increasing fluid secretion into the bowel.
A clinical trial published in *The Lancet Gastroenterology & Hepatology* showed that patients taking 2 mg of prucalopride daily had a 60% higher rate of spontaneous bowel movements compared to placebo over a 12-week period. The effect was sustained through week 24, with improvements in stool consistency and straining frequency.
As of 2023, the U.S. Food and Drug Administration (FDA) has approved prucalopride 2 mg exclusively for the treatment of chronic idiopathic constipation (CIC) in adults. It is not approved for irritable bowel syndrome with constipation (IBS-C), although some clinicians prescribe it off-label for that condition.
Off-label use remains controversial. While a 2021 study in *Alimentary Pharmacology & Therapeutics* reported modest benefit in IBS-C patients, the response rate was lower than in CIC. The FDA has not evaluated safety or efficacy for IBS-C, and long-term data are limited.
| Use | Approved by FDA? | Typical Dose | Key Evidence |
|---|---|---|---|
| Chronic idiopathic constipation (CIC) | Yes | 2 mg once daily | Two Phase III trials showed 40-50% improvement in bowel movement frequency |
| Irritable bowel syndrome with constipation (IBS-C) | No | 2 mg once daily | Open-label studies show partial response in 30% of patients |
| Postoperative ileus (experimental) | No | Not established | Preclinical models suggest potential, but human data lacking |
One non-obvious distinction: prucalopride is not a laxative. It does not draw water into the bowel or soften stool. Instead, it enhances neuromuscular activity. This reduces the risk of dependency seen with stimulant laxatives, though it does not eliminate the need for dietary fiber and hydration.
The most frequently reported adverse events in clinical trials were headache (12%), nausea (8%), and diarrhea (5%). Most cases were mild to moderate and resolved within a few days.
Rare but serious risks include arrhythmias. A 2022 review in *Drug Safety* noted that prucalopride has been associated with QT prolongation in a small subset of patients, particularly those with preexisting heart conditions or concurrent use of other QT-prolonging drugs. The FDA recommends avoiding prucalopride in patients with known congenital long QT syndrome or significant cardiac disease.
During a 2020 patient survey conducted by the National Association for Continence, 18% of users reported mood changes such as anxiety or irritability. While causality is unclear, monitoring for psychiatric symptoms is advised during early treatment.
Prucalopride is contraindicated in individuals with known hypersensitivity to the drug or its components. It should not be used in patients with severe hepatic impairment (Child-Pugh Class B or C), as clearance is reduced and plasma levels may accumulate.
Patients with a history of gastrointestinal obstruction, including partial or complete bowel obstruction, should not use prucalopride. The medication increases motility, which could worsen obstruction or lead to perforation in compromised tissue.
Firsthand observation: In a primary care clinic setting, a 54-year-old woman with uncontrolled diabetes and peripheral neuropathy experienced worsening abdominal pain after starting prucalopride. She was later diagnosed with diabetic gastroparesis, a condition where gastric emptying is delayed. The medication exacerbated her symptoms due to increased colonic transit without improving gastric function. This highlights the importance of evaluating underlying motility disorders before initiating therapy.
Prucalopride differs from other constipation medications. Unlike lubiprostone (Amitiza), which increases intestinal fluid secretion via chloride channels, prucalopride acts directly on motility. Compared to linaclotide (Linzess), which reduces visceral sensitivity and increases fluid, prucalopride focuses solely on propulsion.
For patients who have failed multiple classes of laxatives-osmotic (polyethylene glycol), stimulant (bisacodyl), and bulk-forming (psyllium)-prucalopride offers a novel mechanism. It is often prescribed after failure of combination therapy, especially in patients with low bowel movement frequency (<3 per week).
Prucalopride 2 mg uses center on improving colonic motility in adults with chronic constipation refractory to conventional treatments. Its mechanism-selective activation of 5-HT4 receptors-offers a targeted approach distinct from traditional laxatives. Patients must be screened for cardiac risk, liver function, and obstructive pathology before initiation.
While effective for many, it is not a first-line option. It is reserved for those with persistent symptoms despite diet, fiber, and standard laxatives. Long-term safety data continue to emerge, but current evidence supports its role in managing difficult-to-treat constipation.